行情

FPRX

FPRX

Five Prime
NASDAQ

实时行情|Nasdaq Last Sale

5.57
-0.26
-4.46%
盘后: 5.57 0 0.00% 16:00 01/24 EST
开盘
5.90
昨收
5.83
最高
5.90
最低
5.43
成交量
61.11万
成交额
--
52周最高
13.84
52周最低
3.180
市值
2.03亿
市盈率(TTM)
-1.3421
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FPRX 新闻

  • If You Had Bought Five Prime Therapeutics (NASDAQ:FPRX) Stock Three Years Ago, You'd Be Sitting On A 89% Loss, Today
  • Simply Wall St..01/10 14:28
  • Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference
  • Business Wire.2019/12/30 18:05
  • Longtime biotech exec walks away from board to concentrate on startup
  • American City Business Journals.2019/12/27 19:26
  • Five Prime founder leaves board to focus on startup
  • seekingalpha.2019/12/27 03:01

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

FPRX 简况

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
展开

Webull提供Five Prime Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。